FCM
GTHX

Flinton Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Flinton Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-308
Closed -$13K – 876
2018
Q2 		$13K Sell
308
-1,204
-80% -$51.6K ﹤0.01% 841
2018
Q1 		$56K Buy
+1,512
New +$40.3K ﹤0.01% 808

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flinton Capital Management's GTHX Position: Q3 2018 in Review

Flinton Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2018, closing a stake of 308 shares — an estimated $13K sold.

Flinton Capital Management first reported a position in GTHX in Q1 2018 and held it in 2 quarters. The position peaked at $56K in Q1 2018. 115 funds tracked by Wall St. Rank hold GTHX as of Q3 2018.

  • Flinton Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Flinton Capital Management sold 308 G1 Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $13K.
  • Flinton Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Flinton Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $56K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Flinton Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.